TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis

Joint Bone Spine

Volumn 79, Issue 5, 2012, Pages 471-475

  Daïen, Claire Immediato ^a   Fabre, Sylvie ^a   Rittore, Cécile ^a   Soler, Stephan ^a   Daïen, Vincent ^b   Tejedor, Gautier ^a   Cadart, Doris ^a   Molinari, Nicolas ^c   Daurès, Jean Pierre ^b   Jorgensen, Christian ^a,b   Touitou, Isabelle ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c UMR 729 MISTEA   (France)

Author keywords

Biomarker; Rheumatoid arthritis; Rituximab; SNP; TGF beta1

Indexed keywords

ADALIMUMAB; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 10; LEFLUNOMIDE; LYMPHOTOXIN; METHOTREXATE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; RITUXIMAB; SALAZOSULFAPYRIDINE; STAT4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CODON; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SYNOVITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CYTOKINES; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; STAT4 TRANSCRIPTION FACTOR; TNF RECEPTOR-ASSOCIATED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 84867988986     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.10.007     Document Type: Article

References (31)

1. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
2. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400.
3. Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
4. Duddy M.E., Alter A., Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. J Immunol 2004, 172:3422-3427.
5. Roosnek E., Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991, 173:487-489.
6. Takemura S., Klimiuk P.A., Braun A., et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001, 167:4710-4718.
7. Narvaez J., Hernandez M.V., Ruiz J.M., et al. Rituximab therapy for AA-amyloidosis secondary to rheumatoid arthritis. Joint Bone Spine 2011, 78:101-103.
8. Sellam J., Hendel-Chavez H., Rouanet S., et al. B-cell activation biomarkers as predictive factors of the response to rituximab in rheumatoid arthritis. Arthritis Rheum 2011, 63:933-938.
9. Guis S., Balandraud N., Bouvenot J., et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007, 57:1426-1430.
10. Quartuccio L., Fabris M., Salvin S., et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1557-1559.
11. Teng Y.K., Levarht E.W., Hashemi M., et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007, 56:3909-3918.
12. Thurlings R.M., Vos K., Wijbrandts C.A., et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008, 67:917-925.
13. Kavanaugh A., Rosengren S., Lee S.J., et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008, 67:402-408.
14. Roll P., Dorner T., Tony H.P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008, 58:1566-1575.
15. de Vries N., Tak P.P. The response to anti-TNF-alpha treatment: gene regulation at the bedside. Rheumatology 2005, 44:705-707.
16. Lee Y.H., Rho Y.H., Choi S.J., et al. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006, 27:157-161.
17. Mugnier B., Balandraud N., Darque A., et al. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003, 48:1849-1852.
18. Coenen M.J., Gregersen P.K. Rheumatoid arthritis: a view of the current genetic landscape. Genes Immun 2009, 10:101-111.
19. Boissier M.C Cell and cytokine imbalances in rheumatoid synovitis. Joint Bone Spine 2011, 78:230-234.
20. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
21. Assous N., Gossec L., Dieude P., et al. Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol 2008, 35:31-34.
22. Pokorny V., Chau J., Wu L., et al. Transforming growth factor beta 1 gene (HSTGFB1) nucleotide T869C (codon 10) polymorphism is not associated with prevalence or severity of rheumatoid arthritis in a Caucasian population. Ann Rheum Dis 2003, 62:907-908.
23. Oen K., Malleson P.N., Cabral D.A., et al. Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis. Rheumatology 2005, 44:1115-1121.
24. Prati C., Wendling D. Using targeted therapies alone for rheumatoid arthritis. Joint Bone Spine 2011, 78:1-3.
25. Syrris P., Carter N.D., Metcalfe J.C., et al. Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. Clin Sci 1998, 95:659-667.
26. Awad M.R., El-Gamel A., Hasleton P., et al. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998, 66:1014-1020.
27. Guo Z., Binswanger U., Knoflach A. Role of codon 10 and codon 25 polymorphisms on TGF-beta 1 gene expression and protein synthesis in stable renal allograft recipients. Transplant Proc 2002, 34:2904-2906.
28. Yokota M., Ichihara S., Lin T.L., et al. Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000, 101:2783-2787.
29. Yamada Y., Miyauchi A., Goto J., et al. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 1998, 13:1569-1576.
30. Lebman D.A., Edmiston J.S. The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect 1999, 1:1297-1304.
31. Kehrl J.H, Thevenin C., Rieckmann P., et al. Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J Immunol 1991, 146:4016-4023.